News

Kronos Bio to Showcase Research at Key Medical Conferences

Kronos Bio to Showcase Research at Key Medical Conferences

Kronos Bio to Present Research at Major Medical Conferences

Kronos Bio, Inc. (Nasdaq: KRON), a leader in cancer treatment, is preparing for an exciting lineup of conferences next month. These events underscore their commitment to advancing small molecule therapeutics that specifically target cancers associated with deregulated transcription. Participating in these conferences not only reflects their dedication to research and innovation but also aims to disseminate vital advancements to the global medical community.

Upcoming Conferences

H.C. Wainwright 26th Annual Global Investment Conference

This prestigious conference will take place from September 9 to 11, where Kronos Bio's President and CEO, Norbert Bischofberger, Ph.D., is scheduled to present on September 9 at 2:30 p.m. ET. This session offers a valuable opportunity for investors and stakeholders to understand the company's vision and its clinical progress.

American Association for Cancer Research Ovarian Cancer Research Symposium

On September 20-21, the symposium in Seattle will feature a presentation by Kronos Bio's Director of Translational Development, Luis Carvajal, Ph.D. He will showcase a poster detailing his team's research on KB-0742, an oral CDK9 inhibitor designed for treating recurrent ovarian cancer. The session will also include an author discussion, allowing attendees to engage directly with the researcher.

International Myeloma Society Annual Meeting

Kronos Bio will participate in the International Myeloma Society's 21st Annual Meeting in Rio de Janeiro from September 25 to 28. Collaborator Mariateresa Fulciniti, Ph.D., will deliver an oral presentation on the impact of p300 catalytic inhibition on the growth of multiple myeloma cells. This session is vital as it will shed light on new therapeutic strategies for managing this type of cancer.

Webcast and Research Availability

Kronos Bio is committed to transparency and engagement with its audience by offering a live audio webcast of the H.C. Wainwright presentation. This webcast will be accessible on the company’s website under the Investors & Media section and will be available for replay for 30 days following the event. Additionally, the research posters presented at these medical meetings will also be available on the Kronos Bio website, ensuring that stakeholders and interested individuals can review the latest scientific advancements from the company.

About Kronos Bio

Kronos Bio, Inc. is leading the way in cancer treatment by focusing on small molecule therapeutics that address transcriptional deregulation—an important feature of cancerous cells. The company utilizes a distinctive discovery engine aimed at unraveling complex transcription factor networks, which assists in identifying druggable cofactors essential for tumor-specific conditions. Among their notable developments, Istisociclib (KB-0742) offers a powerful approach to counteract MYC deregulation in solid tumors, while KB-9558 targets IRF4 dependence in multiple myeloma through p300 inhibition.

With its headquarters in San Mateo and a research facility in Cambridge, Kronos Bio is dedicated to fostering innovation in oncological therapies. They encourage all interested parties to learn more by visiting their website.

Frequently Asked Questions

What is Kronos Bio focused on?

Kronos Bio is dedicated to developing small molecule therapeutics for cancer treatment, particularly those related to deregulated transcription.

When is the H.C. Wainwright Conference?

The H.C. Wainwright 26th Annual Global Investment Conference is set for September 9-11, 2024.

Who will present at the AACR Symposium?

At the AACR Symposium, Luis Carvajal, Ph.D., will present a poster discussing the clinical expansion of KB-0742.

How can I access the webcast of the presentation?

The live audio webcast of the H.C. Wainwright presentation will be available on the Kronos Bio website and can be replayed for 30 days afterward.

Is Kronos Bio involved in research collaborations?

Yes, Kronos Bio collaborates with institutions like the Dana-Farber Cancer Institute to enhance their research capabilities and findings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 202

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading
7th World Media Summit Spotlights Media's Future in Beijing

Updated Category News Views 235

The Changing Landscape of Global Media An event of this magnitude doesn't just pop up every day like a stock ticker on Wall Street. This year's 7th World Media Summit in Beijing is where nearly 500 bigwigs from all corners of the media landscape are converging. It's not about trading stocks or hitting quarterly numbers—it's about shaping how stories get told in an era...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 452

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 245

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 267

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 414

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 354

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 337

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 358

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
Adding Fireplaces: Home Comfort or Construction Headache?

Updated Category News Views 276

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Continue Reading

Top 5 Most Recently Viewed Articles

Canadian Stocks Surge: Understanding Market Dynamics and Trends

Updated Category News Views 178

Canadian Stocks See Notable Gains The Canadian stock market has shown encouraging signs of growth lately, with various sectors playing a part in this upward movement. The S&P/TSX Composite Index achieved a remarkable increase of 0.57%, marking a significant point in its trading history. Key Sectors Driving Market Growth The rise in stock prices can largely be credited to...

Continue Reading
Bookmark Medical Enters Michigan Via Village Medical Buy

Updated Category News Views 38

Stepping into Michigan It might not be a Wall Street headliner, but Bookmark Medical's move into Michigan sure says a lot about their growth ambitions. On August 3, 2026, the Nashville-based healthcare group wrapped up acquiring Village Medical Michigan. This is Bookmark's maiden voyage into the Great Lake State, where it's taken over the reins of seven primary care...

Continue Reading
Astrotech Corporation Reports Impressive Year-End Results

Updated Category News Views 134

Astrotech Corporation Reports Strong Fiscal Performance Recently, Astrotech Corporation (NASDAQ: ASTC) announced its financial results for the fiscal year that ended on June 30. The report highlights notable advancements from its subsidiary, 1st Detect, and how these developments are contributing to overall revenue and growth potential. Key Financial Highlights The...

Continue Reading
Neptune Flood Research Highlights Path to Private Insurance Transition

Updated Category News Views 165

Neptune Flood Research Report Offers Insights on NFIP Transition Recent research indicates that private flood insurers may be capable of taking on 95% of policies from the NFIP, helping to mitigate federal financial exposure. Neptune Flood Research Group has published a comprehensive report analyzing the U.S. flood insurance market. The study emphasizes the challenges...

Continue Reading
Valerio Therapeutics Shifts Focus to Early-Stage Drug Development

Updated Category News Views 131

Valerio Therapeutics Announces Strategic Refocus Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) has made a pivotal announcement regarding its strategic business direction. The company has decided to halt all clinical trials, including the ongoing VIO-01 trial. This decision comes in response to significant financing challenges impacting the organization. While...

Continue Reading